Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers

Starting soon · Phase 1

Conditions studied: Healthy Adult

In brief

This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5524 in healthy adult volunteers.

Key facts

Study ID

NCT07349589

Run by

Daewon Pharmaceutical Co., Ltd.

People needed

48

Starts

2026-02-01

Expected to finish

2026-12-01

Last updated by the study team

2026-01-20

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy adult volunteers aged 19 years or older at the time of screening
• Individuals weighing 50.0 kg or more and having a body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening

You may not qualify if…

• Those with a current or past medical history of clinically significant liver, kidney, nervous, mental, respiratory, endocrine, blood disease, tumor, genitourinary, cardiovascular, digestive, or musculoskeletal diseases.

Where it is running

• Chungbuk National University Hospital — Cheongju-si, South Korea

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.